Navigation Links
Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020
Date:10/19/2011

>5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

6.1 Insulin 19

6.2 Oral Medications 19

6.2.1 Sulfonylureas (SUR) 19

6.2.2 Biguanides (BGDs) 19

6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21

6.2.4 Meglitinides 21

6.2.5 Thiazolidinediones (TZDs) 22

6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23

6.2.7 Oral Combination Therapy 23

6.3 Other Injectionable Medications 24

6.3.1 Pramlintide 24

6.3.2 Exenatide 24

6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Syncria 25

7.1 Introduction 25

7.2 Mechanism of Action 25

7.3 Clinical Studies 25

7.4 Factors Affecting Sales of Syncria 26

7.4.1 Once Weekly Dosage 26

7.4.2 Competition from Januvia 26

7.4.3 Approval of Bydureon 26

7.5 Drug Evaluation 27

7.5.1 Drug Risk Benefit Score 27

7.5.2 Intensity of Competition 27

7.6 Sales Forecasts 28

7.6.1 Target Patient Pool for Syncria 28

7.6.2 Dosing 28

7.6.3 Market Penetration 28

7.6.4 Annual Cost of Syncria 28

7.6.5 Sales Projections of Syncria 29

8 Diabetes Market: Appendix 38

8.1 Market Definitions 38

8.2 List of Abbreviations 38

8.3 Research Methodology 38

8.3.1 Coverage 39

8.3.2 Secondary Research 39

8.3.3 Forecasting 39

8.3.4 Net Penetration of Drug 40

8.3.5 Net Annual Dosing 40

8.3.6 Annual Cost of Therapy 40

8.3.7 Primary Research 40

8.3.8 Expert Panels 40

8.4 Drug Sales Estimates Model 41

8.5 Contact Us 41

8.6 Disclaimer 41

8.7 Sources 41

1.1 List of Tables

Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5

Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7

Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
6. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
9. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
10. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
11. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
(Date:7/21/2014)...   Aventura , the leader for instant-on ... that MemorialCare Health System , a top ... at the Orange Coast Memorial Medical Center ... Orange Coast Memorial is a 218-bed general medical ... annually. The Aventura Roaming Aware Desktop (RAD) – ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 3MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 4
... 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that ... Company's prostate cancer drug candidate CB7630,(abiraterone acetate) were ... Conference, which is currently taking place,in Lugano, Switzerland. ... presentations on Sunday, July 8, as part of ...
... Factor Xa Inhibitor,Shows a Significant Reduction in ... Enoxaparin with Similarly Low Bleeding,Rates , GENEVA, ... clinical trial,data presented today at the XXI ... demonstrate that once-daily,rivaroxaban (Xarelto®) achieved superior efficacy ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:7/22/2014)... Hill, South Carolina (PRWEB) July 22, 2014 ... weight loss solution managed to lose 20 pounds. Unfortunately, the ... shaky and nauseated for the duration of her time using ... ‘manic’. One woman experienced heart flutters and insomnia as a ... woman experienced a heart attack at the age of 37 ...
(Date:7/22/2014)... Washington, DC (PRWEB) July 22, 2014 ... pleased to announce the release of Specialty Pharmacy ... the annual book that provides a comprehensive overview of ... year’s update includes management strategies and tactics for:, ... the ensuing cost and utilization concerns — including details ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Cumberland ... providing a dental experience that values anxiety-free dental care ... is essential for a child's dental care. , ... standard of care to infants, adolescents, adults and those ... emotional or physical disability, or require unique care, such ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 NOVAtime ... of enterprise Time and Attendance / Workforce Management ... a NOVAtime 3000 customer since 2007, has upgraded ... version of NOVAtime’s state-of-the-art, web-based time and attendance ... in Iowa (LSI) is a human services agency ...
(Date:7/22/2014)... CareTouch Communications, Inc. has formed a ... Community . CareTouch employees will select causes they are ... in line with their mission to help people in ... first cause is Hike for Hospice, to benefit the ... September 14, the CareTouch in the Community team will ...
Breaking Medicine News(10 mins):Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 3Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2
... less healthy than their English counterparts, but they live as long ... study by researchers from the RAND Corporation and the Institute for ... 55 to 64 have higher rates of chronic diseases than ... And Americans age 65 and older -- while still sicker than ...
... PITTSBURGH, Nov. 3 Medicare patients in regions that spend ... quality care, according to a new study of spending practices ... (GSPH). The findings, published in the Nov. 3 Online First ... reveal great variation across the country in both drug spending ...
... A drug commonly used in Japan and Korea to treat ... cells traditionally resistant to chemotherapy, according to a new study led ... drug approved for use in Japan and South Korea, and not ... more than two decades to treat asthma and other allergic disorders ...
... and the Cincinnati Veterans Affairs (VA) Medical Center have found ... prescribed therapies for high blood pressure do not often adhere ... 2 online edition of the American Journal of Nephrology ... the Cincinnati VA, showed that treatment of hypertension in patients ...
... Goodwin HealthDay Reporter , WEDNESDAY, Nov. 3 (HealthDay ... with autism have a "disconnect" between their frontal lobe and ... show. The disconnect may help explain some ... autism, researchers report in the Nov. 3 issue of ...
... that older adults who wear multifocal contact lenses to ... that increases with age, may have greater difficulty driving ... problems with near vision, medically termed presbyopia, usually occurs ... inability to focus on objects up close. According ...
Cached Medicine News:Health News:Americans less healthy than English, but live as long or longer, study finds 2Health News:Americans less healthy than English, but live as long or longer, study finds 3Health News:Higher medication spending doesn't indicate better prescribing quality 2Health News:Medication adherence improves blood pressure control in chronic kidney disease 2Health News:Gene Associated With Autism May Alter How Brain Functions 2Health News:Gene Associated With Autism May Alter How Brain Functions 3Health News:Multifocal contact lenses may reduce vision for night driving 2
... contain a buffered sodium citrate ... a citrate concentration of 0.109 ... (3.8%). The mixing ratio is ... 9 parts blood. In addition ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
Medicine Products: